Postoperative sore throat has a negative impact on patient satisfaction and recovery. Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug available for topical use. We performed a systematic review and meta-analysis to assess the efficacy and safety of topical application of benzydamine to prevent postoperative sore throat in adults undergoing elective surgery under general anaesthesia. We searched PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials to identify relevant randomised controlled trials and pooled the data using a random effects model. The primary outcomes were the incidence and severity of sore throat 24 h after surgery/extubation, and adverse events. The quality of evidence was assessed using the grading of recommendations, assessment, development and evaluation (GRADE) criteria. Thirteen randomised controlled trials involving 1842 patients were included. Compared with control patients who did not receive analgesia, benzydamine was associated with a decreased incidence of postoperative sore throat, with a risk ratio (95%CI) of 0.31 (0.20-0.47), but not with significantly reduced severity, the standardised mean difference (95%CI) being À0.27 (À0.63 to 0.08). There were no significant adverse events related to benzydamine. Benzydamine was also associated with a reduced incidence of postoperative sore throat when compared with lidocaine, with a risk ratio (95%CI) of 0.18 (0.07-0.43). We judged the evidence for the outcome 'incidence of postoperative sore throat' as high quality.
Introduction
Postoperative sore throat is common, and affects up to 68% of patients undergoing general anaesthesia [1] . It is an undesirable postoperative outcome and negatively impacts patient satisfaction and recovery, even after hospital discharge [2] [3] [4] [5] , so should be prevented. Mucosal erosion by tracheal tube cuffs, mechanical trauma from intubation and inflammation of the mucosa are possible causes for postoperative sore throat [6] [7] [8] [9] [10] . Randomised controlled trials (RCTs) have suggested that anti-inflammatory agents such as inhaled [11] , topical [12, 13] or systemic corticosteroids [14, 15] as well as topical ketamine [16] and benzydamine hydrochloride [17] can prevent postoperative sore throat.
Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug that is available for topical use. A systematic review published in 2014 suggested that topical benzydamine hydrochloride might prevent postoperative sore throat [17] . However, that review included a small number of studies and suffered from publication bias. Since then, several RCTs have examined the efficacy of topical benzydamine hydrochloride for prevention of postoperative sore throat. Here, we present an up-to-date systematic review and metaanalysis of the efficacy and safety of topical benzydamine hydrochloride for prevention of postoperative sore throat in adults undergoing general anaesthesia.
Methods
The conduct and reporting of this systematic review followed the Cochrane Collaboration methodology [18] and PRISMA statement [19] .
The following eligibility criteria were applied: a parallel-group, randomised controlled design comparing topical application of benzydamine hydrochloride with a non-analgesic or active control; enrolment of adults undergoing elective surgery under general anaesthesia; all patients intubated with tracheal tubes; and reporting of postoperative sore throat 24 h after surgery/extubation. No restrictions were applied regarding the formulation or dose of benzydamine hydrochloride used. Non-analgesic controls included: usual care; no lubrication of the tracheal tube; or use of agents without known analgesic effects, such as water or saline. Active controls included agents with a known impact on postoperative sore throat, such as lidocaine, or alternative agents such as dexpanthenol. Studies in which patients underwent head and neck surgery, in which a laryngeal mask airway was placed, or benzydamine hydrochloride was administered in combination with other agents, were excluded.
We searched PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials to identify eligible trials. The reference lists of the publications identified as potentially relevant were also searched to identify further eligible studies. Google Scholar TM was also used to search for potentially relevant articles that prospectively cited eligible trials. No language or publication status restrictions were imposed. The search strategy used is outlined in Supporting Information Table S1 . The search was last updated on 7 December 2017.
Two authors (AK, MA) independently reviewed the articles obtained by the search and selected relevant articles. Disagreement was resolved through discussion.
Using an extraction form, the first author and one of two other authors (MR, KM) independently extracted the following data from each study: patient characteristics (age, sex, ASA physical status); study characteristics (country, type of surgery); interventions used (formulations and doses of benzydamine hydrochloride if reported, comparators, anatomical sites where benzydamine hydrochloride was applied); and relevant outcomes.
The same authors independently assessed the risk of bias (random sequence generation, allocation concealment, blinding, incomplete outcomes data, selective outcomes reporting and other bias) using the Cochrane risk of bias assessment tool [18, 20] . Given that sore throat is a subjective outcome, the study participants were required to be blinded to the type of intervention they received. We also checked for industry sponsorship or conflicts of interest. Any disagreements were resolved by consensus. We attempted to contact the original study authors for more information if an e-mail address was available. We considered study authors to be unresponsive when no reply was received after three attempts at contact. The quality of evidence was assessed as high, moderate, low or very low according to the GRADE (grading of recommendations, assessment, development and evaluation) system [21] [22] [23] .
The primary outcomes were the incidence and severity of postoperative sore throat 24 h after surgery/ extubation, and adverse events in the study groups. The secondary outcomes were the incidence of moderate or severe postoperative sore throat, postoperative cough and postoperative hoarseness 24 h after surgery/ extubation. The risk ratio (RR) and standardised mean difference (SMD) were calculated for dichotomous and continuous outcomes, respectively, and are presented with the corresponding 95% confidence interval (CI). When trials contained zero events in either arm, continuity corrections were used with addition of 0.5 to each cell of 2 9 2 tables from the trial [24] . When trials presented the data as the median with interquartile range, the values were converted to the mean and standard deviation [25] using the method proposed by Wan et al. [26] , or the authors of the studies were asked to provide the converted data. The data were pooled using the DerSimonian and Laird random effects model [27] . Statistical heterogeneity was assessed using the I 2 and Q statistics [28, 29] . Egger's method [30, 31] was used to test for a small study effect or publication bias. Primary analyses were performed for each type of comparator, that is, non-analgesic controls and active controls. The data were pooled into a single arm for primary analysis when a trial included more than one intervention arm. Sub-group analyses were performed according to the site at which benzydamine hydrochloride was applied. The number of study participants in the control group was divided evenly by that in intervention groups for sub-group analysis when trials contained more than one intervention arm. We also performed tests of interaction to detect any differences between the sub-groups according to type of comparator and site of application of benzydamine hydrochloride [32] . We performed meta-regression analyses by age, sex and duration of surgery, all of which are known risk factors for postoperative sore throat [1] , with sample size and dose of benzydamine hydrochloride as potential covariates. Sensitivity analysis was also performed by excluding trials at high or unclear risk of bias in terms of sequence generation, allocation concealment, blinding of participants and outcome assessors, and industry sponsorship.
Trial sequential analysis was performed using the O'Brien-Fleming alpha-spending function method to assess the robustness of the outcomes against type-1 and type-2 errors [33] [34] [35] [36] [37] . A relative risk reduction of 50% for postoperative sore throat was considered clinically meaningful based on the most conservative value from the power calculations presented in the included trials [38] [39] [40] [41] . We maintained a 5% risk of type-1 error and a power of 80%, and required that information size was calculated based on a relative risk reduction of 50% for postoperative sore throat. The threshold for statistical significance was set at p < 0.05. The meta-analysis was performed using Stata SE version 15.0 software (StataCorp., College Station, TX, USA) and the trial sequential analyses were performed using the TSA version 0.9 beta software package (Copenhagen Trial Unit, Copenhagen, Denmark).
Results
Our initial search yielded 1048 titles and abstracts. After applying the study inclusion and exclusion criteria, 13 RCTs involving 1842 study participants were analysed (Supporting Information Fig. S1 ) [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] .
The study participants ranged in age from 36 to 55 years and the proportion of female patients in the studies ranged from 34% to 100% (Table 1) . Ten trials included patients with ASA physical status 1-2 [40, [42] [43] [44] [45] [46] [47] [48] [49] [50] and two included patients with ASA physical status 1-3 [39, 41] ; the remaining trial did not provide details on physical status classification. Nine trials provided details on the types of surgery performed [38-41, 43-46, 48] , which included thoracic, gastro-intestinal, genito-urinary, gynaecological, ophthalmological, orthopaedic and plastic surgery. The median sample size was 90 (range 52-378).
Benzydamine hydrochloride was applied inside the oropharyngeal cavity [38, 40, [43] [44] [45] [46] [47] , along the tracheal tube [49] , to the tracheal tube cuff [38, 39, 42, 48, 50] or to both the tracheal tube cuff and the oropharyngeal cavity [38, 41] . Benzydamine was gargled, sprayed in the oropharyngeal cavity, or lubricated around the tracheal tube cuff. The reported doses of benzydamine hydrochloride ranged from 0.75 to 22.5 mg; four trials did not report the dose [42, [47] [48] [49] . Non-analgesic controls included saline (eight trials) [38, 39, 41-44, 48, 49] , water (two trials) [40, 47] , no lubrication (one trial) [50] , and tartrazine (one trial) [46] . The comparator agents with known analgesic effects were topical lidocaine (four trials) [39, 42, 48, 49] , ketamine (two trials) [44, 45] and aspirin (one trial) [40] . In one trial [47] , the comparator was dexpanthenol, an anti-inflammatory agent. All trials were published in full between 2004 and 2017. Ten trials were published in English, two in Indonesian [45, 49] and one in Turkish [43] . Seven trials used a conventional four-level classification system to rate the severity of postoperative sore throat or to confirm its presence; the other six trials used a trial-specific rating system to grade severity [41-44, 48, 50] . In total, we contacted 13 study authors for further information, five of whom responded with details. Eight trials (62%) included adequate sequence generation and allocation concealment (Table 2 ). Participants and outcome assessors were considered to be adequately blinded in 5 (38%) and 11 (85%) trials, respectively. Eight trials (62%) were deemed to be free from conflicts of interest or sponsorship bias.
Benzydamine hydrochloride vs. non-analgesic controls
Eleven trials including 1364 participants provided data on postoperative sore throat 24 h after surgery/extubation [38] [39] [40] [41] [42] [43] [46] [47] [48] [49] [50] . Topical application of benzydamine hydrochloride was associated with a reduced incidence of postoperative sore throat, RR (95%CI) 0.31 (0.20-0.47), p < 0.001, I 2 = 34.3 ( Fig. 1 ). We performed a metaregression analysis to identify the source of moderate statistical heterogeneity, but found no association with: sample size (p = 0.54); age (p = 0.82); proportion of women (p = 0.193); operating time (p = 0.48); or dose of benzydamine hydrochloride (p = 0.166). There was no evidence of publication bias (p = 0.154). The GRADE quality for this evidence was judged to be high. Five trials involving 786 participants provided data on the severity of postoperative sore throat at 24 h after surgery/extubation [38, 39, 41, 44, 50] . Topical application of benzydamine hydrochloride was not associated with reduced severity of postoperative sore throat, with an SMD (95%CI) of À0.27 (À0.63 to 0.08), p = 0.13, I 2 = 78.5 (Fig. 2) . The GRADE quality of the evidence for this outcome was judged to be very low. Seven trials reported on adverse events, and additional information was obtained from one study author [38, 40, 41, 44, [46] [47] [48] 50] . Numbness, burning sensation, dry mouth, nausea/vomiting and thirst were reported as potential adverse events. None of the RR (95%CI) for the following symptoms were statistically significant: 2.07 (0.27-16.03) for numbness; 1.75 (0.55-5.55) for burning sensation; 0.93 (0.78-1.11) for dry mouth; 0.75 (0.45-1.25) for nausea/vomiting; and 1.04 (0.74-1.45) for excessive thirst.
Three trials including 615 participants provided information on moderate or severe postoperative sore throat 24 h after surgery/extubation [38, 40, 46] . Topical application of benzydamine hydrochloride was associated with a reduced incidence of moderate or severe postoperative sore throat, RR (95%CI) 0.27 (0.14-0.49), p < 0.001, I 2 = 0.0 (Fig. S2) . The GRADE quality for this outcome was judged to be high. Five trials involving 793 participants provided data on postoperative cough 24 h after surgery/extubation [38, 41, 42, 46, 48] . Topical application of benzydamine hydrochloride was not associated with a reduced incidence of postoperative cough, RR (95%CI) 0.59 (0.29-1.20), p = 0.144, I 2 = 55.7 (Fig. S3) . The GRADE quality for this outcome was judged to be very low. Five trials involving 792 participants provided data on postoperative hoarseness 24 h after surgery/extubation [38, 41, 42, 46, 48] . Topical application of benzydamine hydrochloride was associated with a reduced incidence of postoperative hoarseness, RR (95%CI) 0.42 (0.24-0.73), p = 0.002, I 2 = 16.9 (Fig. S4) . The GRADE quality for this outcome was judged to be high. Sub-group analyses based on type of comparator showed that a trial where the tracheal tube was not lubricated as a control demonstrated a statistically smaller effect of benzydamine hydrochloride in preventing postoperative sore throat (p = 0.02; Table S3 ). Sub-group analyses according to the site of application of benzydamine hydrochloride suggested that application around the tracheal tube cuff had limited ability to prevent severe postoperative sore throat (p = 0.002). The results of the sensitivity analyses of the incidence and severity of postoperative sore throat when nonanalgesic controls were used were consistent with those of the primary analyses (Table S3 ). Trial sequential analysis of postoperative sore throat suggested that the cumulative z-curve crossed both the conventional and trial sequential monitoring boundary for benefit before reaching the required information size (439 patients), thereby suggesting a true positive effect of benzydamine hydrochloride in the prevention of postoperative sore throat (Fig. S4) .
Benzydamine hydrochloride vs. active controls
Seven comparative effectiveness trials used analgesic agents as the comparator. The comparator was lidocaine in four trials [39, 42, 48, 49] , ketamine in two trials [44, 45] and aspirin and dexpanthenol in one trial each [40, 47] .
When compared with lidocaine, benzydamine hydrochloride was associated with a reduced incidence of postoperative sore throat, RR (95%CI) 0.18 (0.07-0.43), p = 0.037, I 2 = 0.0 (Fig. 4 ) and postoperative hoarseness, RR (95%CI) 0.54 (0.30-0.97), p = 0.047, I 2 = 0.0. However, there was no evidence of a difference in the severity of postoperative sore throat, SMD (5%CI) 0.00 (À0.25 to 0.25); p = 1.00, one study only) or incidence of postoperative cough, RR (95%CI) 0.42 (0.14-1.25), p = 0.117, I 2 = 0.0. The GRADE quality for the incidence of postoperative sore throat and postoperative hoarseness was judged to be high, whereas the quality for the remaining two was very low. Figure 1 Selection of studies included in the meta-analysis.
Topical application of benzydamine hydrochloride was not superior to ketamine for postoperative sore throat or cough, aspirin for postoperative sore throat or dexpanthenol for postoperative sore throat.
The results of the sensitivity analyses for the incidence of postoperative sore throat when the comparator was lidocaine were consistent with those of the primary analyses (Table S4) . Trial sequential analysis for postoperative sore throat suggested that the cumulative z-curve crossed both the conventional and trial sequential monitoring boundary for benefit before reaching the required information size (279 patients). This finding suggested a true positive effect of benzydamine hydrochloride compared with that of lidocaine for prevention of postoperative sore throat (Fig. S5) .
Discussion
Postoperative sore throat is common, important to patients and affects quality of recovery [51] . However, although there are exceptions [52] , much airway research does not assess postoperative sore throat, even though complications are noted [53] [54] [55] . In this systematic review of the literature, topical application of benzydamine hydrochloride was associated with a reduced incidence of postoperative sore throat in comparison with non-analgesic controls and lidocaine irrespective of the dose. The number needed to prevent postoperative sore throat when using topical benzydamine hydrochloride was 6 (95%CI 5-8), indicating a large prophylactic effect. Use of benzydamine hydrochloride prevented postoperative hoarseness and tended to reduce postoperative cough. The limited evidence available suggests that benzydamine hydrochloride is not associated with significant adverse events. The consistent robustness of our sensitivity and trial sequential analyses suggests that topical application of benzydamine hydrochloride prevents postoperative sore throat.
However, there was inconsistency between the effects of benzydamine hydrochloride on the incidence and severity of postoperative sore throat. There are some potential explanations for this. First, the trials that failed to mitigate postoperative sore throat were more focused on assessment of severity. The incidence of postoperative sore throat was not significantly reduced in 4 out of the 11 trials included in our analysis, whereas three of five included trials failed to show a reduction in severity. Second, the number of trials that could be included in the meta-analysis of severity was smaller than the number that could be included for incidence (5 vs. 11) . This might have resulted in wider confidential intervals, although the summary estimate of severity tended to favour benzydamine hydrochloride. Our secondary analysis also indicates that moderate and severe postoperative sore throat was significantly reduced by benzydamine hydrochloride, which suggests that the severity of postoperative sore throat was mitigated. Along with the tendency of benzydamine hydrochloride to reduce severity, as seen in our secondary analysis, topical benzydamine hydrochloride may decrease the severity of postoperative sore throat when used prophylactically.
Our sub-group analysis found that, although there was a consistent tendency for benzydamine hydrochloride to decrease the incidence and severity of postoperative sore throat, there were differences in incidence according to the type of comparator used and in severity according to the application site. Compared with other sub-groups (i.e. saline or water), a trial that used no lubrication of the tube as a control showed smaller prophylactic efficacy on postoperative sore throat [50] , for which there is no explanation or supporting evidence. Trials that included application of benzydamine hydrochloride around the tracheal cuff reported less prophylactic efficacy in reducing the severity of postoperative sore throat. Mucosal irritation at the level of the tracheal tube cuff is considered to be a cause of tracheal morbidity [7] , and we speculate that application at this point would reduce the incidence and severity of postoperative sore throat. The limited number of trials that assessed severity of postoperative sore throat could have lent more weight to trials suggesting that benzydamine was not effective, and led to this paradoxical result.
Our review could not fully assess all adverse events related to benzydamine hydrochloride. The CONSORT (consolidated standards of reporting trials) statement published in 1996 requires that trial investigators report on harms associated with interventions [56] . All 13 trials were published after publication of this statement, but only seven reported on harms (in addition, one study author provided data on our request). Each adverse event was reported in only three to six trials. In contrast with the previous review, our analysis of the limited evidence available suggests that topical use of benzydamine hydrochloride is not associated with a greater risk of adverse events. However, other reviews have suggested that numbness and a burning sensation may be attributable to the topical use of benzydamine hydrochloride [17, 57] .
A previous systematic review including five RCTs published by Chen et al. in 2014 suggested that topical benzydamine hydrochloride might prevent postoperative sore throat [17] . Our analysis was consistent with their findings. However, there are four important differences between the two reviews. First, the previous review included one RCT that investigated patients in whom laryngeal mask airways were placed [58] , whereas we only included RCTs that assessed patients whose tracheas were intubated. Second, the number of studies included in our analysis was almost three times that in the previous review. Third, we included studies published in languages other than English, which made our review more comprehensive. Fourth, the previous study reported evidence of publication bias, whereas our analysis found no such evidence (p = 0.154). Therefore, we believe that our study overcame the limitations of the previous study, and was able to find evidence supporting the efficacy of benzydamine hydrochloride as a prophylactic measure for postoperative sore throat.
Previous systematic reviews have suggested that topical lidocaine [59] and ketamine [16] could prevent postoperative sore throat. Our systematic review found that although topical benzydamine hydrochloride was superior to topical lidocaine, it was no better than topical use of ketamine in preventing postoperative sore throat. However, the effects of benzydamine hydrochloride and ketamine on the incidence of postoperative sore throat have only been compared in small trials [44, 45] . More trials are needed to determine the ability of benzydamine hydrochloride to prevent postoperative sore throat in comparison with other analgesic agents.
This systematic review has some important strengths. First, we conducted an exhaustive literature search and identified 13 studies. This relatively large number of trials allowed us to perform relevant sub-group, sensitivity and meta-regression analyses, the results of which have some clinically important implications. Second, our review included some comparative effectiveness trials. Topical lidocaine is known to prevent postoperative sore throat [16, 59] , and was compared with benzydamine hydrochloride. In our analysis, benzydamine hydrochloride was superior to lidocaine in preventing postoperative sore throat. Third, we used the Cochrane methodology when performing this systematic review. We contacted the original study authors when necessary to minimise the risk of bias and supplement necessary information in each trial. We also examined the quality of evidence using the GRADE criteria and confirmed the robustness of our findings using sub-group, sensitivity and trial sequential analyses.
This work also has several limitations. First, we could not determine an optimal dose of benzydamine hydrochloride; however, our meta-regression analysis found that there was no association of dose with effect size. Moreover, our sub-group analysis according to site of application suggests that postoperative sore throat may be prevented if benzydamine hydrochloride is applied in the oropharyngeal cavity. Second, the trials included contained bias that could not be eliminated by contacting the original authors. However, the results of sensitivity analyses with a low risk of bias in each domain were consistent with those of the primary analysis [60] . Given that sore throat is a subjective outcome, we strictly required that participants receiving the allocated interventions were blinded, and the sensitivity analysis with regard to blinding of study participants still demonstrated significant efficacy for benzydamine hydrochloride. We also used the GRADE criteria to assess the impact of the risk of bias in the included trials on the evidence. In conventional meta-analyses and trial sequential analyses, topical benzydamine hydrochloride was associated with a reduction in the incidence (although not in the severity) of postoperative sore throat when compared with non-analgesic and lidocaine control groups. Furthermore, although data on side-effects are more limited, benzydamine does not appear to cause adverse effects.
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